Literature DB >> 25367880

Circulating MicroRNA as Potential Source for Neurodegenerative Diseases Biomarkers.

Ying Zi1,2, Zhongmin Yin3, Weizhong Xiao4, Xinwei Liu5, Zhixiang Gao6, Li Jiao7, Lianfu Deng8.   

Abstract

An increasing number of circulating micro-ribonucleic acids (microRNAs, miRNAs) have been discovered its potential as biomarkers to diagnose neurodegenerative diseases (NDs) by many researchers. However, there were obvious inconsistencies among previous studies, and thus we performed this meta-analysis to evaluate whether miRNA is an effective biomarker with high accuracy to diagnose the NDs. PubMed, MEDLINE, EMBASE, the Cochrane Library, and other related databases were used to search eligible articles. The data of sensitivity and specificity were employed to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the SROC curve (AUC). I (2) test were used to estimate the heterogeneity among different studies. In addition, the possible sources of heterogeneity were further explored by subgroup analyses and meta-regression. All analyses were performed by STATA 12.0 software. In this meta-analysis, eight publications with 459 NDs patients and 340 healthy controls were included to investigate the diagnostic performance of circulating miRNAs for NDs. The overall sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ration (NLR), and diagnostic odds ratio (DOR) were 0.83 (95% confidence interval (CI) 0.77-0.88), 0.87 (95% CI 0.83-0.89), 6.2 (95% CI 4.9-7.9), 0.19 (95% CI 0.14-0.27), 33 (95% CI 20-52), and 0.91 (95% CI: 0.88-0.93), respectively. The overall SROC curve was plotted with AUC of 0.91 (95% CI 0.88-0.93), which indicated an excellent diagnostic performance of circulating miRNA for NDs. Subgroup analysis based on miRNA profile demonstrated that multiple-miRNA assay had higher diagnostic accuracy for NDs when compared with single-miRNA assay. In conclusion, the circulating miRNAs may be the potential biomarkers in the clinical diagnosis of NDs, and the diagnostic accuracy would be better by using multiple-miRNA assay. However, large-scale studies are still needed to explore the relation between the circulating miRNA dysregulation and the pathological mechanism of NDs.

Entities:  

Keywords:  Circulating; Meta-analysis; MicroRNAs; Molecular marker; Neurodegenerative diseases

Mesh:

Substances:

Year:  2014        PMID: 25367880     DOI: 10.1007/s12035-014-8944-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  41 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Authors:  Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2009-05

3.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

4.  Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples.

Authors:  Yang Zhang; Qi Zhong; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2014-06-19

5.  Biomarkers for Parkinson's disease.

Authors:  Todd B Sherer
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

6.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

7.  MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.

Authors:  Chen-Geng Liu; Jin-Ling Wang; Lei Li; Pei-Chang Wang
Journal:  Int J Mol Med       Date:  2014-05-13       Impact factor: 4.101

8.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

9.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

10.  MicroRNA expression in Alzheimer blood mononuclear cells.

Authors:  Hyman M Schipper; Olivier C Maes; Howard M Chertkow; Eugenia Wang
Journal:  Gene Regul Syst Bio       Date:  2007-12-20
View more
  6 in total

1.  Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Authors:  Marta Cosín-Tomás; Anna Antonell; Albert Lladó; Daniel Alcolea; Juan Fortea; Mario Ezquerra; Albert Lleó; Maria José Martí; Mercè Pallàs; Raquel Sanchez-Valle; José Luís Molinuevo; Coral Sanfeliu; Perla Kaliman
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

2.  Wide Profiling of Circulating MicroRNAs in Spinocerebellar Ataxia Type 7.

Authors:  Verónica M Borgonio-Cuadra; Claudia Valdez-Vargas; Sandra Romero-Córdoba; Alfredo Hidalgo-Miranda; Yessica Tapia-Guerrero; César M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Mol Neurobiol       Date:  2019-02-05       Impact factor: 5.590

3.  Genome-wide identification of microRNA-related variants associated with risk of Alzheimer's disease.

Authors:  Mohsen Ghanbari; M Arfan Ikram; Hans W J de Looper; Albert Hofman; Stefan J Erkeland; Oscar H Franco; Abbas Dehghan
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

4.  Improved Detection of Circulating miRNAs in Serum and Plasma Following Rapid Heat/Freeze Cycling.

Authors:  Peter D Mariner; Armin Korst; Anis Karimpour-Fard; Brian L Stauffer; Shelley D Miyamoto; Carmen C Sucharov
Journal:  Microrna       Date:  2018

5.  MicroRNA-212-5p Prevents Dopaminergic Neuron Death by Inhibiting SIRT2 in MPTP-Induced Mouse Model of Parkinson's Disease.

Authors:  Sifan Sun; Xiaojuan Han; Xueting Li; Qiqi Song; Ming Lu; Miaomiao Jia; Jianhua Ding; Gang Hu
Journal:  Front Mol Neurosci       Date:  2018-10-11       Impact factor: 5.639

6.  Evaluation of RNA isolation methods for microRNA quantification in a range of clinical biofluids.

Authors:  Henk P Roest; Jan N M IJzermans; Luc J W van der Laan
Journal:  BMC Biotechnol       Date:  2021-08-06       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.